{"id":"W2621656000","doi":"10.1016/s1470-2045(17)30404-7","title":"Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Eisai; National Institute for Health and Care Research; Cancer Research UK; University College London; Les Laboratories Pierre Fabre; AstraZeneca; Celgene; Genomic Health; Research England; Pfizer; Amgen","keywords":"Epirubicin; Medicine; Capecitabine; Cyclophosphamide; Breast cancer; Internal medicine; Fluorouracil; Gastroenterology; Chemotherapy; Cancer; Surgery; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003872509,0.001979137,0.003458608,0.0005287835,0.0004512706,0.001238472,0.0009918573,0.001939234,0.004899378],"category_scores_gemma":[0.003742989,0.0007166806,0.002241446,0.0005898002,0.001518729,0.001237564,0.0004752172,0.002844085,0.0006406485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00101578,"about_ca_system_score_gemma":0.001258033,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001410717,"about_ca_topic_score_gemma":0.002686484,"domain_scores_codex":[0.9977464,0.00160253,0.0001198232,0.0002326547,0.00009185149,0.0002067433],"domain_scores_gemma":[0.9978061,0.0006483868,0.0006719318,0.0001812938,0.0001037291,0.0005884796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9934149,0.001888175,0.0001609477,0.0001995048,0.0002632461,0.00001416381,0.00001689522,0.0001322129,0.0005495438,0.00003827016,0.0001817659,0.003140323],"study_design_scores_gemma":[0.939499,0.05873083,0.0007741377,0.00002105088,0.0002654264,0.00001989229,0.000008635129,0.0002325708,0.0001534504,0.00007082355,0.0002155725,0.000008636513],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870459,0.005260297,0.0006012967,0.0005872534,0.0008835126,0.00356464,0.0005664066,0.00008562714,0.001405079],"genre_scores_gemma":[0.9889643,0.002084288,0.001298293,0.0006802054,0.0006963462,0.003927538,0.0005383588,0.00001978115,0.001790761],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004899378,"threshold_uncertainty_score":0.02048004,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08496628285504446,"score_gpt":0.4261559906783022,"score_spread":0.3411897078232577,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}